Evidence map›Paper›PMID 29120861›Full record

Trial reportDrug and alcohol dependence2018

Preventing relapse to smoking with transcranial magnetic stimulation: Feasibility and potential efficacy.

Christine E Sheffer, Warren K Bickel, Thomas H Brandon, Christopher T Franck, Darwin Deen, Luana Panissidi, Syed Amir Abdali, Jami C Pittman, Sara E Lunden, Neelam Prashad and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Comparing neuromodulation targets to reduce cigarette craving and withdrawal: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christine E ShefferCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA; Roswell Park Cancer Institute, Carlton House, Room 402, Buffalo, NY 14263, USA, USA. Electronic address: Christine.sheffer@roswellpark.org.
Warren K BickelAdvanced Recovery Research Center, Virginia Tech Carilion Research Institute, 2 Riverside Circle, R-3113, Roanoke, VA 24016, USA. Electronic address: wkbickel@vtc.vt.edu.
Thomas H BrandonMoffitt Cancer Center, Tobacco Research and Intervention Program,4115 East Fowler Avenue Tampa, FL 33617, USA. Electronic address: thomas.brandon@moffitt.org.
Christopher T FranckDepartment of Statistics, Virginia Tech, 403-E Hutcheson Hall (MC 0439), 250 Drillfield Drive Blacksburg, VA 24061, USA. Electronic address: chfranck@vt.edu.
Darwin DeenCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: ddeen@med.cuny.edu.
Luana PanissidiCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: Lpanissidi87@gmail.com.
Syed Amir AbdaliCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: saabdali@med.cuny.edu.
Jami C PittmanCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: Jami.c.pitt@gmail.com.
Sara E LundenCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: saralunden@gmail.com.
Neelam PrashadCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: Prashad.neelam@gmail.com.
Ria MalhotraCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: rmalhot000@citymail.cuny.edu.
Antonio MantovaniCity University of New York School of Medicine, City College of New York, Harris Hall, 160 Convent Ave, New York, NY 10031, USA. Electronic address: amantovani@med.cuny.edu.

Funding

Translational Research Training on Addictions for Racial/Ethnic MinoritiesR25DA035161 · NIDA · CITY COLLEGE OF NEW YORK · PI DENISE AIMEE HIEN, Lesia Monique Ruglass · 2013 to 2026
$4.4M
Enhancing relapse prevention for smoking cessation with rTMSR21CA178813 · NCI · CITY COLLEGE OF NEW YORK · PI MANTOVANI, ANTONIO, SHEFFER, CHRISTINE ELIZABETH · 2014 to 2015
$387k
NCI NIH HHS R21 CA178813NIDA NIH HHS R25 DA035161
6 · The paper itself

Abstract

Many smokers attempt to quit every year, but 90% relapse within 12 months. Converging evidence suggests relapse is associated with insufficient activation of the prefrontal cortex. Delay discounting rate reflects relative activity in brain regions associated with relapse. High-frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (LDLPFC) increases cortical excitability and reduces delay discounting rates, but little is known about feasibility, tolerability, and potential efficacy for smoking cessation. We hypothesized that 8 sessions of 20Hz rTMS of the LDLPFC combined with an evidence-based self-help intervention will demonstrate feasibility, tolerability, and potential efficacy in a limited double-blind randomized control trial. Smokers (n=29), abstinent for 24h, motivated to quit, and not using cessation medications, were randomized to active 20Hz rTMS at 110% of Motor Threshold or sham stimulation that replicated the look and sound of active stimulation. Stimulation site was located using the 6cm rule and neuro-navigation. Multiple clinical, feasibility, tolerability, and efficacy measures were examined. Active rTMS decreased delay discounting of $100 (F (1, 25.3694)=4.14, p=.05) and $1000 (F (1, 25.169)=8.42, p<.01), reduced the relative risk of relapse 3-fold (RR 0.29, CI 0.10-0.76, Likelihood ratio χ2 with 1 df=6.40, p=.01), increased abstinence rates (active 50% vs. sham 15.4%, Χ

Indexed as

AdultCigarette SmokingDouble-Blind MethodFeasibility StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPilot ProjectsPrefrontal CortexRecurrenceSecondary PreventionSmoking CessationTranscranial Magnetic StimulationTreatment OutcomeFeasibilityRelapse preventionSmoking cessationTranscranial magnetic stimulation

Identifiers

PMID29120861
PMCPMC5836507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.